Japanese pharma double ticked

Japanese company Kyowa Kirin is gearing up to file its human monoclonal antibody Crysvita for the treatment of X-linked hypophosphataemia locally after the TGA granted the company two designations.

The regulatory body granted the drug priority review and orphan drug designation this week for the treatment of adults and paediatric patients with the rare condition.

X-linked hypophosphataemia causes low levels of phosphate in the blood which leads to impaired bone growth and development.